Phio Pharmaceuticals (PHIO)
Develops PH-762, a self-delivering RNAi therapy injected into skin tumors.
Something off on this page? Send us feedback.
Develops self-delivering RNAi therapeutics centered on investigational intratumoral PH-762 for skin tumors, with no product sales because it has no approved drug; the focused development model relies on outsourced work, regulatory progress and external capital.
Develops INTASYL, a self-delivering RNAi platform designed to silence selected proteins without a separate delivery vehicle. Its only active human clinical candidate, PH-762, is administered directly into accessible skin tumors to target the immune-checkpoint protein PD-1; it remains investigational with no approved product line.
Runs a narrow, Massachusetts-based clinical-development operation rather than commercial drug franchises, serving trial participants, investigators, regulators, prospective partners, contract manufacturers and capital providers. Work beyond its small internal program relies on external clinical and manufacturing organizations, including commercial-scale supply preparation for PH-762.
Future economics depend on regulatory approval, commercialization or partnership arrangements, and access to outside capital. Progress is concentrated in an early clinical program whose development, enrollment, supply, regulatory review and clinical evidence remain key dependencies.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $13.0M · Total debt $0 · Total assets $14.3M · Shareholders' equity $12.6M
- Revenue
- $0
- Operating income
- −$4.3M
- Net income
- −$4.1M
No dividends on record.
| Institutions24 holders · as of Mar 31, 2026 | 5.75% | 668.5K shares | |
| Insiders10 holders · as of Aug 20, 2026 | 16.22% | 1.88M shares | |
| Strategic holders1 holder · as of Feb 17, 2026 | 10.28% | 1.19M shares | |
| Otherremainder | 67.75% | 7.87M shares |
11.62M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
CVI Investments, Inc.Strategic | 10.28% | 1.19M | 13Gfiled Feb 17, 2026 ↗ |
Mitchell P. KopinInsider | 9.83% | 1.14M | 13Gfiled Feb 13, 2026 ↗ |
Robert J. BittermanInsiderdirector, officer: Chairman, Pres. & CEO | 3.71% | 431,421 | Form 4filed Aug 19, 2026 ↗ |
Geode Capital Management, LLCInstitution | 1.27% | 147,254 | 13Fas of Mar 31, 2026 |
Jane Street Group, LLCInstitution | 1.03% | 119,189 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 19, 2026 | Ronald Todd Plott | director | +15,000 | $1.14 |
| Aug 18, 2026 | Robert J. Bitterman | director, officer: Chairman, Pres. & CEO | +10,000 | $1.06 |
| Jun 26, 2026 | Robert J. Bitterman | director, officer: Chairman, Pres. & CEO | +10,000 | $0.9900 |
| Dec 31, 2025 | Robert J. Bitterman | director, officer: Chairman, Pres. & CEO | +5,000 | $1.03 |
| Dec 23, 2025 | Robert J. Bitterman | director, officer: Chairman, Pres. & CEO | +5,000 | $1.02 |
- Merck
Established PD-1 blockade across all three PH-762 trial indications.
- Regeneron
Systemic PD-1 blockade in advanced cutaneous squamous-cell carcinoma.
- Incyte
Approved PD-1 option in Merkel cell and cutaneous squamous-cell carcinoma.
- Bristol-Myers Squibb
Systemic PD-1 treatment in melanoma.
- Amgen
Intralesional immunotherapy for unresectable melanoma.
- Replimune Group
Intratumoral oncolytic-immunotherapy development in melanoma.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Phio Pharmaceuticals | $1.15 | +1.77% | $13.1M | — | — | — | — |
| Merck | $151.72 | +0.05% | $374.52B | 121.3 | 17.6 | 5.6 | +5.1% |
| Regeneron | $851.82 | −0.02% | $87.78B | 21.1 | 14.1 | 5.7 | +16.7% |
| Incyte | $128.82 | +3.05% | $26.11B | 16.4 | 53.4 | 4.5 | +37.7% |
| Bristol-Myers Squibb | $67.65 | −0.01% | $138.21B | 14.9 | 10.6 | 2.8 | +5.7% |
| Amgen | $443.00 | +0.04% | $239.00B | 27.5 | 18.9 | 6.3 | +9.7% |
| Replimune Group | $15.90 | −0.50% | $1.34B | — | — | — | — |
| Median | 21.1 | 17.6 | 5.6 | +9.7% |